Oruka Therapeutics, Inc.
NASDAQOruka Therapeutics enters its June 2 earnings event riding a contradictory setup: the stock is down 12% over the past month to $55.01, yet options traders have turned sharply more optimistic than at any point in recent memory. The options signal is the standout. The put/call ratio collapsed to 0.36 on June 1 — more than two standard deviations below its 20-day average of 0.65. That…
ORKA short interest drops 31% in one week to 12.6% of float, retreating from recent highs as availability remains ample at 209%.
Snapshot as of 2 Jun 2026
Oruka Therapeutics enters its June 2 earnings event riding a contradictory setup: the stock is down 12% over the past month to $55.01, yet options traders have turned sharply more optimistic than at any point in recent…
Oruka Therapeutics heads into its May 20 earnings call with one of the most aggressive short-interest buildups seen in the small-cap biotech space this year — and a Street that, for now, is pointing firmly in the…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for ORKA — free to start on ORTEX.
Sign up for free →Open ORKA on ORTEX